Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Blocking protein quality control to counter hereditary cancers

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Novel fusion genes and chimeric transcripts in ependymal tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Trisomy 8 in pediatric acute myeloid leukemia: A NOPHO-AML study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Caroline Kampmeyer
  • Sofie V Nielsen
  • Lene Clausen
  • Amelie Stein
  • Anne-Marie Gerdes
  • Kresten Lindorff-Larsen
  • Rasmus Hartmann-Petersen
Vis graf over relationer

Inhibitors of molecular chaperones and the ubiquitin-proteasome system have already been clinically implemented to counter certain cancers, including multiple myeloma and mantle cell lymphoma. The efficacy of this treatment relies on genomic alterations in cancer cells causing a proteostatic imbalance, which makes them more dependent on protein quality control (PQC) mechanisms than normal cells. Accordingly, blocking PQC, e.g. by proteasome inhibitors, may cause a lethal proteotoxic crisis in cancer cells, while leaving normal cells unaffected. Evidence, however, suggests that the PQC system operates by following a better-safe-than-sorry principle and is thus prone to target proteins that are only slightly structurally perturbed, but still functional. Accordingly, implementing PQC inhibitors may also, through an entirely different mechanism, hold potential for other cancers. Several inherited cancer susceptibility syndromes, such as Lynch syndrome and von Hippel-Lindau disease, are caused by missense mutations in tumor suppressor genes, and in some cases, the resulting amino acid substitutions in the encoded proteins cause the cellular PQC system to target them for degradation, although they may still retain function. As a consequence of this over-meticulous PQC mechanism, the cell may end up with an insufficient amount of the abnormal, but functional, protein, which in turn leads to a loss-of-function phenotype and manifestation of the disease. Increasing the amounts of such proteins by stabilizing with chemical chaperones, or by targeting molecular chaperones or the ubiquitin-proteasome system, may thus avert or delay the disease onset. Here, we review the potential of targeting the PQC system in hereditary cancer susceptibility syndromes.

OriginalsprogEngelsk
TidsskriftGenes Chromosomes and Cancer
Vol/bind56
Udgave nummer12
Sider (fra-til)823-831
Antal sider9
ISSN1045-2257
DOI
StatusUdgivet - dec. 2017

ID: 52408812